HomeNovelEvaluate pharmaceutical companies’ partnership agreements with RNA-targeted drug discovery companies
Evaluate pharmaceutical companies’ partnership agreements with RNA-targeted drug discovery companies
January 6, 2023
DUBLIN, January 6, 2023 /PRNewswire/ — The “New RNA-Targeting Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA and regRNA Targeting, and More: An Overview Review of technologies, goals, business and finance from an Industry Perspective report has been added.” ResearchAndMarkets.com offering.
This report provides a landscape overview and analysis of the discovery and development of new RNA-targeted drug modalities from an industrial perspective.
The report evaluates pharmaceutical companies’ partnership agreements with RNA-targeted drug discovery companies in terms of agreement scope and economic terms that help identify the preferences of major pharmaceutical companies for ways of targeting new drugs. ‘RNA.
In recent years, the pharmaceutical industry has increased its efforts to identify novel drug targets outside the usual G protein-coupled receptors, ion channels, and enzymes of multiple families, including kinases, in order to provide a greater variety of treatment options for patient populations in a number of disease states. In this context, recent attention has turned to the search for regulators of RNA function, including small molecules and biological products.
Previously considered “difficult to drug” on a structural and selective basis, substantial efforts in academia and industry are now focusing on targeting RNA as a therapeutic modality. These efforts are driven both by the biological significance of RNAs and by a growing number of studies implicating the biology of aberrant RNA in many human diseases.
RNAs mediate cellular processes such as regulation of gene transcription, splicing, and enhancement or inhibition of protein activity. Not surprisingly, based on the myriad of important functions of cellular RNAs, their dysregulation is often associated with disease phenotypes, and RNA molecules are increasingly recognized as potential targets for drug development efforts.
Small molecule and oligonucleotide-based therapies are being pursued with the goal of targeting RNA biology. This broad range of approaches, which also includes targeting of RNA and RNA-binding proteins and RNA-modifying enzymes, is in line with the known complexity of RNA biology and regulation.
Although it is now recognized that many RNAs can adopt complex protein-like tertiary structures, classically, RNA has been targeted in a sequence-based rather than a structure-based way. Antisense oligonucleotides (ASOs) remain a potent class of biological products for sequence-based RNA targeting.
Each approach is presented in a separate chapter based on individual company profiles, technology profiles, and drug or drug candidate profiles.
Technology company profiles address the following:
General overview (founders, year of foundation, technology source, location, number of employees), main company activities
Financing history and financial situation
Goals and pipeline
The RNA-targeting drug modalities covered by this report are:
The report addresses for each approach to targeted RNA with new treatment modalities:
Industry stakeholders, i.e. technology companies, pharmaceutical partners, and investors
RNA target discovery technologies and RNA targeted drug discovery
Selected RNA targets for drug discovery and associated clinical indications or therapeutic areas
Preclinical and/or clinical experience with novel RNA-targeting drug modalities
Funding history and financial situation of RNA technology companies
Partnership agreements (collaborations for discovery and/or development, licensing, acquisitions)
Benchmarking of technology companies based on technology validation by data, partnerships and investors
What will you find in the report?
Profiles of diverse and pure-play RNA targeting pharmaceutical technology companies
Description of Major Pharma’s role in the industry (partnerships, acquisitions and investments)
Comprehensive description and analysis of emerging technologies for RNA target discovery and drug delivery
Selection of RNA doping technology and preferences of major pharmaceutical companies
Pharmacological profiles of novel RNA-targeted drugs and drug candidates
Target selection, pipeline analysis and drug candidate competition
Description and analysis of funding rounds (capital raised, investors)
Economic conditions of collaboration and license agreements
Who will benefit from the report?
Venture capital, private equity and investment managers
Manager of Big Pharma venture capital firms
Business Development and Licensing (BDL) specialists.